Holen Sie sich die Stockscreener-App
68.87
0.06%
0.04
Vorhandelsmarkt:
68.87
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
B of A Securities Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - Nasdaq
ARWR: B of A Securities Raises Price Target Amid Maintained Buy Rating | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals Flourishes with Key Milestones and Growth Projections - StocksToTrade
Arrowhead Pharmaceuticals stock soars after dosing first subjects in trial By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals stock soars after dosing first subjects in trial - Investing.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 1-Year HighTime to Buy? - MarketBeat
Arrowhead Hits the Mark - Los Angeles Business Journal
Arrowhead’s Plozasiran Garners FDA Breakthrough Recognition - timothysykes.com
Arrowhead (ARWR) Begins Trials for Alzheimer's Treatment - GuruFocus
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - Business Wire
Marshall Wace LLP Grows Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Norges Bank Invests $30.41 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
(ARWR) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Edgestream Partners L.P. Lowers Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 5%What's Next? - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Price Target Increased by 17.24% to 59.24 - Nasdaq
Franklin Resources Inc. Purchases Shares of 81,226 Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (ARWR) and Humana (HUM) - The Globe and Mail
How Arrowhead Pharmaceuticals Inc. (HDP1) stock reacts to Fed tighteningEarnings Recap Summary & Risk Managed Investment Entry Signals - Newser
How analysts revise price targets for Arrowhead Pharmaceuticals Inc. (HDP1) stockPortfolio Value Report & Reliable Price Breakout Alerts - Newser
What dividend safety rating applies to Arrowhead Pharmaceuticals Inc. (HDP1) stockWeekly Loss Report & Long-Term Capital Growth Strategies - Newser
Is Arrowhead Pharmaceuticals Inc. (HDP1) stock cheap vs fundamentalsJuly 2025 Institutional & Intraday High Probability Alerts - Newser
Breakthrough Approved: FDA approves pioneering FCS drug by Pasadena company - Pasadena Weekly
HC Wainwright Issues Pessimistic Estimate for ARWR Earnings - MarketBeat
What is HC Wainwright's Estimate for ARWR Q2 Earnings? - MarketBeat
Why Arrowhead Pharmaceuticals Inc. (HDP1) stock is favored by hedge fundsJuly 2025 Summary & Low Drawdown Trading Strategies - Newser
Arrowhead Pharmaceuticals Poised for Growth Following Breakthrough FDA Approvals - StocksToTrade
ARWR’s Meteoric Rise: Can It Sustain? - timothysykes.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 52-Week High After Analyst Upgrade - MarketBeat
ARWR: Plozasiran launch, pipeline advances, and strong partnerships drive growth and innovation - TradingView
Arrowhead (ARWR) Stock Sees 9.7% Rise Following Market Activity - GuruFocus
Arrowhead Pharmaceuticals Soars with FDA Breakthrough Therapy Designation - timothysykes.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Arrowhead Pharma stock price target raised to $85 by H.C. Wainwright - Investing.com UK
Have Arrowhead Pharmaceuticals Insiders Been Selling Stock? - simplywall.st
Creative Planning Buys 19,194 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
How Arrowhead Pharmaceuticals Inc. (HDP1) stock behaves under inflation pressure2025 Valuation Update & Accurate Entry and Exit Point Alerts - Newser
Will Arrowhead Pharmaceuticals Inc. (HDP1) stock outperform global peers2025 Macro Impact & AI Enhanced Trading Alerts - Newser
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Mauro Ferrari Sells 8,750 Shares - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 4.7% on Analyst Upgrade - MarketBeat
Arrowhead Pharmaceuticals stock hits 52-week high at 59.19 USD By Investing.com - Investing.com India
Arrowhead Pharmaceuticals stock hits 52-week high at 59.19 USD - Investing.com
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Share Price Boosted 33% But Its Business Prospects Need A Lift Too - 富途牛牛
Bank of America Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Gains FDA Breakthrough Therapy Designation - GuruFocus
Arrowhead Pharmaceuticals gets FDA Breakthrough Therapy status for plozasiran - Seeking Alpha
Arrowhead (ARWR) Gains FDA Breakthrough Therapy Status for Ploza - GuruFocus
Arrowhead rises as U.S. FDA grants breakthrough tag for rare blood fat disorder drug - TradingView
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
HC Wainwright & Co. Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - Nasdaq
Arrowhead Pharmaceuticals receives FDA breakthrough therapy designation for plozasiran - marketscreener.com
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation For Plozasiran - TradingView
Arrowhead Pharma (ARWR): HC Wainwright Raises Price Target to $8 - GuruFocus
FDA grants breakthrough therapy status to Arrowhead’s triglyceride drug - Investing.com
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia - Business Wire
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry - simplywall.st
Will Arrowhead Pharmaceuticals Inc. (HDP1) stock issue positive guidanceJuly 2025 Update & Short-Term High Return Ideas - Newser
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insider Sell: Mauro Ferrari Sells 8,750 Shares of Arrowhead Phar - GuruFocus
Arrowhead Pharmaceuticals Surprises Market with FDA Approval and Financial Turnaround - StocksToTrade
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):